Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. Allan JN, et al. Among authors: taverna p. Haematologica. 2022 Apr 1;107(4):984-987. doi: 10.3324/haematol.2021.280061. Haematologica. 2022. PMID: 34937320 Free PMC article. Clinical Trial. No abstract available.
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC, Müller A, Dheenadayalan RP, Endres S, Roessner PM, Seyfried F, Walliser C, Wist M, Qi J, Tausch E, Mertens D, Fox JA, Debatin KM, Meyer LH, Taverna P, Seiffert M, Gierschik P, Stilgenbauer S. Jebaraj BMC, et al. Among authors: taverna p. Blood. 2022 Feb 10;139(6):859-875. doi: 10.1182/blood.2021011516. Blood. 2022. PMID: 34662393 Free article.
Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy.
Fazio C, Covre A, Cutaia O, Lofiego MF, Tunici P, Chiarucci C, Cannito S, Giacobini G, Lowder JN, Ferraldeschi R, Taverna P, Di Giacomo AM, Coral S, Maio M. Fazio C, et al. Among authors: taverna p. Front Pharmacol. 2018 Dec 7;9:1443. doi: 10.3389/fphar.2018.01443. eCollection 2018. Front Pharmacol. 2018. PMID: 30581389 Free PMC article.
A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients.
Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, Camidge DR. Byers LA, et al. Among authors: taverna p. Oncotarget. 2017 Aug 3;8(46):81441-81454. doi: 10.18632/oncotarget.19888. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113403 Free PMC article.
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C, Hever-Jardine MP, von Herrmann KM, Yim CY, Tam J, Warzecha JM, Shin L, Bock SE, Curran BS, Chaudhry AS, Kim F, Sandusky GE, Taverna P, Freemantle SJ, Christensen BC, Einhorn LH, Spinella MJ. Albany C, et al. Among authors: taverna p. Oncotarget. 2017 Jan 10;8(2):2949-2959. doi: 10.18632/oncotarget.13811. Oncotarget. 2017. PMID: 27936464 Free PMC article.
Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Phillip CJ, et al. Among authors: taverna p. J Hematol Oncol. 2016 Oct 13;9(1):110. doi: 10.1186/s13045-016-0335-5. J Hematol Oncol. 2016. PMID: 27737688 Free PMC article. No abstract available.
Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.
Jueliger S, Lyons J, Cannito S, Pata I, Pata P, Shkolnaya M, Lo Re O, Peyrou M, Villarroya F, Pazienza V, Rappa F, Cappello F, Azab M, Taverna P, Vinciguerra M. Jueliger S, et al. Among authors: taverna p. Epigenetics. 2016 Oct 2;11(10):709-720. doi: 10.1080/15592294.2016.1214781. Epub 2016 Sep 20. Epigenetics. 2016. PMID: 27646854 Free PMC article.
Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.
Riccadonna C, Yacoub Maroun C, Vuillefroy de Silly R, Boehler M, Calvo Tardón M, Jueliger S, Taverna P, Barba L, Marinari E, Pellegatta S, Bassoy EY, Martinvalet D, Dietrich PY, Walker PR. Riccadonna C, et al. Among authors: taverna p. PLoS One. 2016 Aug 31;11(8):e0162105. doi: 10.1371/journal.pone.0162105. eCollection 2016. PLoS One. 2016. PMID: 27579489 Free PMC article.
81 results